Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
Featured trial
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

  • 258 views
  • 08 Dec, 2020
  • 1 location
Featured trial
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

  • 87 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

  • 68 views
  • 08 Dec, 2020
  • 1 location
Featured trial
Barriers to Alzheimer’s Disease (AD) Clinical Trial Participation in Racially Diverse Population of Hawaii

Barriers to Alzheimer’s Disease (AD) Clinical Trial Participation in Racially Diverse Population of Hawaii Authors: Anson Y Lee1,2, Darrell Guittu1,3, Rexton Suzuki1,4, Lauren Pak1,5, Kyle M Ishikawa, MS2,6, Connor Goo1,2, John J Chen, PhD2,6, Enrique Carrazana, MD1, Jason Viereck, MD, PhD1, Kore K Liow, MD1,2 1Memory Disorders Center & Alzheimer’s …

mini-mental state examination
  • 0 views
  • 22 Aug, 2022
  • 1 location
Featured trial
Vascular Contributions to Mechanisms and Biomarkers of Alzheimer’s Disease

This study is managed by Temple University Alzheimer’s Center in collaboration with Crozer Keystone Health System. NO drug involvedThe study will evaluate longitudinally whether the presence of cardiovascular (CV) risk factors (particularly hypertension and hyperhomocysteinemia), in an age and gender-matched population including cognitive normal, subjects with mild cognitive impairment (MCI) …

Accepts healthy volunteers
mild cognitive impairment
cognitive decline
cognitive impairment
  • 16 views
  • 09 Sep, 2022
  • 1 location
Featured trial
A Phase Ii, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Ro4602522 Added To The Background Therapy Of The Acetylcholinesterase Inhibitors Donepezil Or Rivastigmine In Patients With Moderate Severity Alzheimer's Disease

A Phase Ii, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Ro4602522 Added To The Background Therapy Of The Acetylcholinesterase Inhibitors Donepezil Or Rivastigmine In Patients With Moderate Severity Alzheimer's Disease

  • 174 views
  • 25 Mar, 2021
  • 1 location
Multi-omics Research of Idopathic Normal Pressure Hydrocephalus (iNPH)

The research is designed to study the prognostic factors of ventriculoperitoneal (VP) shunt for iNPH by multi-omics research

  • 0 views
  • 18 Aug, 2021
  • 1 location
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease

The purpose of this study is to measure safety and efficacy of buntanetap capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months. The double-blind treatment duration will be up to 6 months. There will be 5 in-clinic …

mini-mental state examination
  • 5 views
  • 15 Sep, 2022
  • 5 locations
Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease (Von2B)

The working hypothesis is that patients with Von Willebrand Disease-type 2B may have neurological symptoms due to the chronic formation of platelets/Von Willebrand Factor aggregates. Interestingly, several patients present nonspecific neurological symptoms (nystagmus, headaches, memory disorder, …) which may be associated with cerebral microangiopathy and chronic microvessel inflammation secondary to …

  • 5 views
  • 14 Sep, 2022
  • 1 location
The Effect of Repetitive Transcranial Magnetic Stimulation on the Cognition in People With Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disease. The cardinal symptoms of PD are tremor, rigidity, bradykinesia and postural instability. Cognitive impairment and dementia are also one of the key features of the non-motor symptoms of PD. At present, the mainstream treatment of PD-dementia is the dopaminergic rivastigmine. …

  • 0 views
  • 13 Apr, 2021
  • 1 location